Similar articles

• Roflumilast for the treatment of chronic obstructive pulmonary disease.

  Antoniu SA. Antoniu SA. Curr Opin Investig Drugs. 2006 May;7(5):412-7. Curr Opin Investig Drugs. 2006. PMID: 16729716 Review.
• Phosphodiesterase inhibitors in airways disease.

  Fan Chung K. Fan Chung K. Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. doi: 10.1016/j.ejphar.2005.12.059. Epub 2006 Feb 2. Eur J Pharmacol. 2006. PMID: 16458289 Review.
• [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].

  Xia XD, Dai YR, Xu ZJ. Xia XD, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jan;27(1):57-9. Zhonghua Jie He He Hu Xi Za Zhi. 2004. PMID: 14989829 Review. Chinese. No abstract available.
• Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.

  Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE. Chapman RW, et al. Eur J Pharmacol. 2007 Oct 1;571(2-3):215-21. doi: 10.1016/j.ejphar.2007.05.074. Epub 2007 Jun 16. Eur J Pharmacol. 2007. PMID: 17610865
• The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.

  Karish SB, Gagnon JM. Karish SB, et al. Ann Pharmacother. 2006 Jun;40(6):1096-104. doi: 10.1345/aph.1E651. Epub 2006 May 30. Ann Pharmacother. 2006. PMID: 16735669 Review.